SC 52458

Known as: SC-52458 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1993-1996
01219931996

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1997
1997
We have previously reported on the basic pharmacologic properties of SC-52458 (5-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl) methyl]-2… (More)
Is this relevant?
1997
1997
This study was designed to assess in normal volunteers the potency, efficacy, and tolerability of the new nonpeptidic, orally… (More)
Is this relevant?
1997
1997
The present experiment demonstrates that the exposure of angiotensin II (AII) produced an up-regulation of the AT2 receptor mRNA… (More)
Is this relevant?
1997
1997
We have previously reported on the basic (by 35%) and SC-52458 was still measurable in plasma from treated dogs. In dogs made… (More)
  • figure 2
  • table 1
  • figure 5
  • figure 4
Is this relevant?
1996
1996
1. The effects of angiotensin (Ang) II receptor antagonist, SC-52458, on peak and plateau components of Ang II-induced… (More)
Is this relevant?
1996
1996
Effects of angiotensin II on ATP release were evaluated in segments and cultured smooth muscle cells from the guinea-pig taenia… (More)
  • figure 1
  • figure 2
Is this relevant?
1994
1994
The in vivo effects of alacepril (1-[(S)-3-acetylthio-2-methylpropanoyl]- L-prolyl-L-phenylalanine), an angiotensin converting… (More)
Is this relevant?
1993
1993
We describe the pharmacologic properties of SC-52458, 5-[(3,5-dibutyl-1H-1,2,4-triazol-1-yl)methyl]-2-[2-(1H-tetrazol - 5… (More)
Is this relevant?